The STPT to AWE token swap window closes on September 21, 2026. After this date, STPT tokens held in personal wallets or on exchanges that did not process the swap in 2025 cannot be exchanged for AWE tokens. The swap is a 1:1 exchange from STPT on Ethereum to AWE on Base, with no project fees but network fees apply. Holders must use the official portal to swap, and those with STPT on Base must bridge tokens back to Ethereum first, requiring a seven-day waiting period, making September 14 the practical deadline for them. Unclaimed AWE tokens after the deadline will be subject to a community vote on their fate. Tax treatment generally carries over acquisition dates and costs, but holders should document transactions carefully. This deadline mainly affects self-custody holders, as major exchanges handled swaps automatically in 2025.
Verisk Analytics introduced its new Verisk Fraud Discovery platform to enhance fraud prevention for insurers. Barclays adjusted the company's price target to $225, suggesting a 21.1% potential gain from the current stock price of $185.79. The company...
Adobe Inc. is undergoing a rare CEO transition with Anil Chakravarthy set to become CEO on December 1. Analyst opinions are divided: Oppenheimer rates Adobe as 'Perform' (hold), while Bank of America issues a 'Sell' rating with a $220 price target, c...
Canaan Inc. reported Q2 2026 results with an EPS loss of $0.01, better than the expected $0.10 loss, showing improved profitability. However, revenue was $4.63 million, below the $5.91 million forecast, indicating weaker sales in its crypto mining ha...
UBS analyst Gavin Parsons upgraded Lockheed Martin to a Buy rating with a $674 price target, implying a 28.3% potential gain. The aerospace and defense firm secured a $729 million contract with Sweden for its Himars rocket system, contributing to a r...
Investment firm BMO Capital downgraded Amgen's stock from "Outperform" to "Market Perform" following a major clinical trial failure by Novartis for a similar cholesterol drug. Novartis' drug pelacarsen failed in a late-stage Phase III trial, casting ...
